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BACKGROUND
Cancers result from the accumulation of somatic mutations, and their properties 
are thought to reflect the sum of these mutations. However, little is known about 
the effect of the order in which mutations are acquired.
METHODS
We determined mutation order in patients with myeloproliferative neoplasms by 
genotyping hematopoietic colonies or by means of next-generation sequencing. 
Stem cells and progenitor cells were isolated to study the effect of mutation order 
on mature and immature hematopoietic cells.
RESULTS
The age at which a patient presented with a myeloproliferative neoplasm, acquisi-
tion of JAK2 V617F homozygosity, and the balance of immature progenitors were 
all influenced by mutation order. As compared with patients in whom the TET2 
mutation was acquired first (hereafter referred to as “TET2-first patients”), patients 
in whom the Janus kinase 2 (JAK2) mutation was acquired first (“JAK2-first pa-
tients”) had a greater likelihood of presenting with polycythemia vera than with 
essential thrombocythemia, an increased risk of thrombosis, and an increased 
sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro. Mutation order influ-
enced the proliferative response to JAK2 V617F and the capacity of double-mutant 
hematopoietic cells and progenitor cells to generate colony-forming cells. More-
over, the hematopoietic stem-and-progenitor-cell compartment was dominated by 
TET2 single-mutant cells in TET2-first patients but by JAK2–TET2 double-mutant 
cells in JAK2-first patients. Prior mutation of TET2 altered the transcriptional con-
sequences of JAK2 V617F in a cell-intrinsic manner and prevented JAK2 V617F from 
up-regulating genes associated with proliferation.
CONCLUSIONS
The order in which JAK2 and TET2 mutations were acquired influenced clinical 
features, the response to targeted therapy, the biology of stem and progenitor 
cells, and clonal evolution in patients with myeloproliferative neoplasms. (Funded 
by Leukemia and Lymphoma Research and others.)
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Cancers evolve as a consequence of the stepwise accumulation of somatic le-sions, with competition between subclones 
and sequential subclonal evolution.1,2 Darwinian 
selection of variant subclones results in acquisi-
tion of biologic attributes required for tumor 
formation.3 Genetic interaction is central to this 
process, but it is unclear how mutated genes 
interact to generate the phenotypic hallmarks of 
cancer, and the influence, if any, of the order in 
which mutations are acquired is unknown.4
Cooperation between different genetic lesions 
has been observed in cell-line models of trans-
formation5 and in mouse models of several can-
cers.6,7 Moreover, the consequences of an early 
lesion may influence the range of subsequent 
mutations that are able to confer a growth ad-
vantage; this concept, which is borrowed from 
population genetics, is termed functional buffer-
ing or genetic canalization.4,8 However, several 
lesions can occur as either early or late events in 
the same tumor type,3,9 suggesting that the final 
malignant properties of a tumor reflect the sum 
of its driver mutations rather than the order in 
which they arose.
The myeloproliferative neoplasms are chronic 
myeloid diseases with several tractable character-
istics. It is possible to obtain enriched fractions 
of stem cells and progenitor cells from periph-
eral blood and to grow clonal populations contain-
ing a sufficient number of cells for genotyping and 
phenotypic analysis.10 This allows direct compari-
son of genetically distinct subclones within a 
patient, thereby controlling for differences in age, 
sex, therapy, genetic background, and other con-
founding variables. Myeloproliferative neoplasms 
also reflect an early stage of tumorigenesis that 
is inaccessible in most cancers, and their long-term 
clinical course permits longitudinal studies. We 
have investigated the influence of mutation order 
in patients with myeloproliferative neoplasms that 
carry mutations in both Janus kinase 2 (JAK2) and 
TET2; mutations in both genes are present in about 
10% of patients with myeloproliferative neoplasms.
Me thods
Patients and Samples
We screened 246 patients with a JAK2 V617F mu-
tation for mutations in TET2. All patients provided 
written informed consent. Diagnoses were made 
in accordance with the guidelines of the British 
Committee for Standards in Haematology. (Details 
on the ethical approval and sample collection are 
provided in Supplementary Appendix 1, available 
with the full text of this article at NEJM.org.)
Isolation of Hematopoietic Stem and 
Progenitor Cells and Clonal Assays
Individual hematopoietic colonies were grown 
from peripheral-blood mononuclear cells, picked, 
and genotyped with the use of Sanger sequencing 
for JAK2 and TET2 mutations. Hematopoietic 
stem-and-progenitor-cell fractions were isolated 
as described previously.11 One population (lin−
CD34+CD38−CD90+CD45RA−) was enriched for 
both hematopoietic stem cells and hematopoietic 
progenitor cells (hereafter referred to as “hema-
topoietic stem and progenitor cells”). For single-
cell cultures, hematopoietic stem and progenitor 
cells were sorted into 96-well plates supplement-
ed with cytokines that were previously shown to 
support progenitor expansion.12 (Further details 
are provided in the Methods section in Supple-
mentary Appendix 1.)
Analysis of Gene Expression and Mutation 
Screening
Colonies of erythroid burst-forming units were 
picked, genotyped, and then pooled for expression-
array analysis (ArrayExpress accession number, 
E-MTAB-3086). Previously published sequencing 
data13 were used to screen for recurrent driver mu-
tations in 10 patients; 13 other patients were 
screened with the use of targeted sequencing for 
111 genes or genetic regions implicated in myeloid 
cancers14 (Table S2 in Supplementary Appendix 1).
Statistical Analysis
Unless otherwise indicated, all comparisons were 
made with the use of the two-sided Student’s t-test. 
We used GraphPad Prism software, version 5.01, 
for all statistical analyses with the chi-square test, 
the Mann–Whitney test, and Student’s t-test. Mul-
tivariate analyses were performed with the use of 
R statistical software. Exome and targeted se-
quencing data were analyzed as described in Sup-
plementary Appendix 1.
R esult s
Stable Clonal Heterogeneity in Chronic-
Phase Myeloproliferative Neoplasms
To identify patients who carried mutations in both 
JAK2 and TET2, we sequenced all exons of the TET2 
gene in 246 patients (92 patients with essential 
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thrombocythemia, 107 with polycythemia vera, and 
47 with myelofibrosis) who carried JAK2 V617F. 
TET2 mutations were identified in 24 patients (7 
with essential thrombocythemia, 11 with polycy-
themia vera, and 6 with myelofibrosis) (Table S1 in 
Supplementary Appendix 1), from whom more than 
7000 individual hematopoietic colonies were JAK2 
and TET2 mutations (Fig. 1A) to establish mutation 
order (Fig. 1B). Subclones containing only the first 
mutation were more common in patients with poly-
cythemia vera and in patients with essential throm-
bocythemia than in patients with myelofibrosis 
(P = 0.01 for the comparison between patients with 
polycythemia vera and those with myelofibrosis, 
and P = 0.02 for the comparison between patients 
with essential thrombocythemia and those with 
myelofibrosis, by the Mann–Whitney test); these 
findings are consistent with the fact that myelofi-
brosis is a more advanced disease (Fig. 1C).
We observed considerable clonal stability with-
in individual patients. First, clones carrying either 
mutant TET2 alone or mutant JAK2 alone were 
readily detected in all 24 patients (median disease 
duration, 7.3 years) (Fig. S1 and Table S2 in Sup-
plementary Appendix 1), suggesting that double-
mutant clones do not rapidly outcompete single-
mutant clones. Second, in 9 patients in whom the 
TET2 mutation was acquired before the JAK2 muta-
tion (hereafter referred to as “TET2-first patients”), 
JAK2 V617F was detected 12 to 112 months before 
the colony analysis. This indicates that TET2 sin-
gle-mutant and TET2–JAK2 double-mutant clones 
coexisted for at least these periods (data not 
shown). Third, it was possible to repeat colony 
assays in new samples obtained from 12 patients 
(4 with essential thrombocythemia, 4 with poly-
cythemia vera, and 4 with myelofibrosis) after in-
tervals of 1 to 3.7 years (Fig. 1D, and Fig. S2 and 
Table S2 in Supplementary Appendix 1). The clonal 
pattern of most patients was very stable; of 44 
subclones identified at the first time point, only 
3 became undetectable at the later time point.
TET2 Mutations Preceding or Following JAK2 
V617F, and the Effect of Mutation Order on 
Disease Biology
JAK2 and TET2 mutations each occurred first in 
12 of 24 patients (Fig. 2A). TET2 mutations arose 
in both JAK2 V617F–heterozygous and JAK2 
V617F–homozygous cells, indicating that JAK2 
V617F homozygosity is not required for, nor 
does it prevent, subsequent acquisition of a TET2 
mutation.
At presentation, TET2-first patients were, on 
average, 12.3 years older than patients in whom 
the JAK2 mutation was acquired first (referred to 
as “JAK2-first patients”) (mean age at diagnosis, 
71.5 years vs. 59.2 years; P = 0.004 by Student’s 
t-test) (Fig. S3A in Supplementary Appendix 1). The 
age difference remained significant after adjust-
ment for disease phenotype (P = 0.02 by two-way 
analysis of variance) and sex (P = 0.007 by two-way 
analysis of variance). Although blood counts at 
presentation did not differ significantly between 
the JAK2-first and TET2-first patients, they were 
influenced by disease phenotype (Table S1 in 
Supplementary Appendix 1).
As compared with TET2-first patients, JAK2-first 
patients had a striking increase in the proportion 
of JAK2 V617F–homozygous colonies of erythroid 
burst-forming units (P<0.001 by the t-test) (Fig. 2B). 
We then studied more immature progenitors from 
13 patients and 3 healthy persons (Fig. 2C, and 
Fig. S3B, S3C, and S3D in Supplementary Appen-
dix 1). In TET2-first patients, there was a predomi-
nance of common myeloid progenitors over other 
progenitors within the CD34+CD38+ compartment 
(P = 0.001 by the t-test). By contrast, megakaryocyte 
and erythrocyte progenitors were more prevalent 
in JAK2-first patients (P<0.001 by the t-test).
To exclude the possibility that additional mu-
tations contributed to the observed differences 
between JAK2-first and TET2-first patients, we per-
formed exome13 or targeted14 sequencing in 23 of 
24 patients. Only 4 patients harbored mutations 
known to be recurrent in myeloid cancers (Table S3 
in Supplementary Appendix 1).15 These data show 
that the effects of mutation order were not con-
founded by other known oncogenic mutations, but 
they do not exclude the possibility that additional 
rare drivers might also influence clinical and 
pathologic phenotypes. Together these data indi-
cate that the age at which patients present with 
myeloproliferative neoplasms, the acquisition of 
JAK2 V617F homozygosity, and the balance of im-
mature progenitors are all influenced by mutation 
order.
Influence of Mutation Order on Proliferation 
of Hematopoietic Stem and Progenitor Cells
To extend our findings to the hematopoietic stem-
and-progenitor-cell compartment, we studied the 
properties of individual hematopoietic stem and 
progenitor cells from patients with both single-
mutant and double-mutant clones. We isolated 
and individually cultured single lin−CD34+CD38−
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CD90+CD45RA− cells16 for 10 days in conditions 
that were previously shown to support the growth 
of multipotent progenitors12 (Fig. S4A in Supple-
mentary Appendix 1). We then measured the pro-
liferation, progenitor content, and genotype of 
individual clones.
In JAK2-first patients, JAK2 single-mutant clones 
were significantly larger than nonmutant clones 
(P = 0.047 by the t-test) and double-mutant 
clones (Fig. 3A) (P = 0.04 by the t-test). This shows 
that proliferation of hematopoietic stem and pro-
genitor cells was enhanced by acquisition of a 
JAK2 mutation on a TET2-nonmutant background 
(i.e., JAK2-first patients) but not on a TET2-mutant 
background (i.e., TET2-first patients). We next as-
sessed the number of progenitors created in the 
10-day cultures with the use of secondary colony 
assays (Fig. 3B). JAK2 V617F reduced progenitor 
formation when it was acquired after a TET2 mu-
tation (P = 0.002), but TET2 mutations increased 
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progenitor expansion when they were acquired 
after JAK2 V617F (P = 0.01). Progenitor expansion 
of individual double-mutant hematopoietic stem 
and progenitor cells was therefore starkly differ-
ent in TET2-first patients and JAK2-first patients.
Effect of Mutation Order on Clonal 
Composition of the Hematopoietic  
Stem-and-Progenitor-Cell Compartment
We next genotyped clones derived from single he-
matopoietic stem and progenitor cells and found 
that the hematopoietic-stem-and-progenitor-cell 
compartment was dominated by single-mutant 
cells in TET2-first patients but by double-mutant 
cells in JAK2-first patients (Fig. 3C). These results 
could reflect a longer interval between acquisition 
of the two mutations in TET2-first patients. How-
ever, in TET2-first patients, the JAK2 V617F muta-
tion was detectable in the earliest available DNA 
sample (a mean of 5 years before the hematopoiet-
ic-stem-cell and progenitor-cell assay). This shows 
that the double-mutant clone had at least this 
amount of time to expand. Furthermore, individu-
al double-mutant hematopoietic stem and progeni-
tor cells obtained from JAK2-first patients created 
more progenitors in vitro than did hematopoietic 
stem and progenitor cells obtained from TET2-first 
patients (Fig. 3B); this suggests an increased intrin-
sic ability to expand at the level of stem and pro-
genitor cells. We therefore favor an interpretation 
that acquisition of a TET2 mutation enhances the 
fitness of JAK2 single-mutant hematopoietic stem 
cells, whereas acquisition of a JAK2 mutation does 
not enhance the fitness of TET2 single-mutant he-
matopoietic stem cells.
Genotyping of the compartment of erythroid 
burst-forming units from the same patients re-
vealed that in JAK2-first patients, the frequencies of 
single-mutant and double-mutant colonies in that 
compartment resembled those seen in the hemato-
poietic-stem-and-progenitor-cell compartment 
(Fig. 3D and 3C). However, in TET2-first patients, 
double-mutant erythroid colonies were more preva-
lent than TET2 single-mutant colonies (P = 0.003 by 
the t-test), a result that contrasts with the genotype 
distribution in hematopoietic stem and progenitor 
cells. The clonal architecture of purified progenitor 
fractions was studied in four patients (Fig. S4B in 
Supplementary Appendix 1). In JAK2-first pa-
tients, the same genotype distributions through-
out the hematopoietic hierarchy were retained, 
whereas in TET2-first patients, the proportion of 
double-mutant cells was increased in megakaryo-
cyte and erythroid progenitors and erythroid 
burst-forming units as compared with earlier 
progenitors. These results indicate that in TET2-
first patients, acquisition of JAK2 V617F, although 
not associated with expansion of hematopoietic 
stem and progenitor cells, does give rise to ex-
pansion of committed erythroid progenitors.
Our results suggest that in TET2-first pa-
tients, TET2 single-mutant hematopoietic stem 
and progenitor cells expand but do not give rise 
to excess differentiated megakaryocytic and ery-
Figure 1 (facing page). JAK2 V617F Preceding or Follow-
ing TET2 Mutations in Patients with Chronic-Phase  
Myeloproliferative Neoplasms.
As shown in Panel A, colonies of erythroid burst-forming 
units (BFU-E) were grown in a semisolid medium from pe-
ripheral-blood mononuclear cells obtained from patients 
with myeloproliferative neoplasms who carried mutations 
in TET2 and JAK2. Colonies (20 to 200 per patient, >7000 
total) were picked and individually sequenced to determine 
the clonal composition and order in which mutations were 
acquired. In Panels B and D, the letters and numbers at 
the top of each column are patient-identification numbers 
for individual patients. Numbers beside the patient-identi-
fication numbers indicate the total number of colonies in 
that patient genotyped, with the percentages of total colo-
nies of each genotype shown below. The circles beside 
these percentages are proportional to the percentages. In 
each of these 3 patients with myeloproliferative neoplasms 
who had long-standing disease, the time from diagnosis 
was 61 months (in a patient with essential thrombocythe-
mia [ET], left column), 67 months (in a patient with polycy-
themia vera [PV], middle column), and 16 months (in a pa-
tient with myelofibrosis [MF], right column). A similar level 
of clonal heterogeneity was present in the majority of 24 
patients with myeloproliferative neoplasms (see Fig. 1 in 
Supplementary Appendix 1). The mean total duration of 
disease was 80 months in patients with polycythemia vera, 
97 months in patients with essential thrombocythemia, 
and 85 months in patients with myelofibrosis. J denotes 
JAK2 V617F mutation, JJ JAK2 V617F homozygosity, NM 
nonmutated, and T TET2 mutation. In Panel C, the stacked 
column plot indicates the mutational status of colonies in 
patients with polycythemia vera, essential thrombocythe-
mia, and myelofibrosis. The total number of colonies per 
patient is shown at the top of each column; average per-
centages are shown in cases of repeated assays. Heterozy-
gous and homozygous acquisitions of mutations were 
each counted as separate mutational events. Subclones 
containing only the first mutation were more common in 
patients with polycythemia vera (P = 0.01 by the Mann–
Whitney test) and essential thrombocythemia (P = 0.02 by 
the Mann–Whitney test) than in patients with myelofibro-
sis. The clonal composition was determined in 12 patients 
with myeloproliferative neoplasms at intervals of 12 to 44 
months; 2 representative patients are shown in Panel D. 
Disappearance of clones over the observed time period 
was rare, with just 3 of 44 clones falling below detection in 
follow-up samples.
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throid cells until subsequent acquisition of a JAK2
mutation. By contrast, in JAK2-first patients, JAK2
single-mutant hematopoietic stem and progenitor 
cells do not expand until acquisition of a TET2
mutation, but they are able to generate increased 
numbers of megakaryocytic and erythroid cells.
 Prior Mutation of TET2 and an Altered 
Transcriptional Response to JAK2 V617F
To study the molecular mechanisms underlying 
the biologic differences associated with distinct 
mutation orders, we performed transcriptional 
profiling on individual nonmutant, single-mutant, 
Figure 2. Effect of Mutation Order on Disease Phenotype.
In Panel A, the pie chart shows the order of acquisition of mutations in 24 patients. Half the patients with myeloproliferative 
neoplasms acquired the JAK2 mutation first ( JAK2-first) and half acquired the TET2 mutation first (TET2-first). Both orders 
of acquisition of mutations occur in each disease subtype. ET denotes essential thrombocythemia, MF myelofibrosis, and 
PV polycythemia vera. In Panel B, the bar graph shows the proportion of JAK2 V617F–homozygous colonies in the total 
number of mutant colonies. Patients in whom JAK2 V617F was acquired first had a greater proportion of homozygous colo-
nies in the mutant compartment (mean percentage of homozygous mutant colonies in JAK2-first patients, 57.8%, vs. 1.4% 
in TET2-first patients; P<0.001 by the t-test). Patients are indicated by their patient-identification numbers. T bars indicate 
standard errors. In Panel C, the bar graph shows the relative number of progenitor cells in the TET2-first patients and JAK2-
first patients. The three bars represent the relative number of common myeloid progenitors (CMPs) (lin−CD34+CD38+CD90−
CD10−FLK2+CD45RA−), granulocyte–macrophage progenitors (GMPs) (lin−CD34+CD38+CD90−CD10−FLK2+CD45RA+), and 
megakaryocyte–erythroid progenitors (MEPs) (lin−CD34+CD38+CD90−CD10−FLK2−CD45RA−). TET2-first patients had a uni-
form predominance of CMPs over other progenitors within the CD34+CD38+ compartment (P = 0.001 by the t-test). By con-
trast, in JAK2-first patients, MEPs were more prevalent than CMPs or GMPs (P<0.001 by the t-test). When the samples were 
obtained, the ages of the TET2-first and JAK2-first patients were similar (mean age, 78 years [range, 66 to 86] vs. 72 years 
[range, 50 to 84]).
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and double-mutant erythroid colonies in samples 
obtained from seven patients (four TET2-first pa-
tients and three JAK2-first patients). More than 500 
colonies were picked and pooled according to JAK2 
or TET2 genotype, with at least 10 colonies of each 
genotype in each sample. This strategy allows di-
rect comparison of genetically distinct cells within 
a patient, thus controlling for differences in age, 
sex, treatment, genetic background, and other 
confounding variables.10
Mutation of JAK2 or TET2 was associated with 
altered patterns of gene expression that were 
strikingly dependent on the antecedent genotype 
(Fig. S5A in Supplementary Appendix 1, and Sup-
plementary Appendix 2, available at NEJM.org). 
For example, most genes that were up-regulated 
or down-regulated when JAK2 V617F was acquired 
on a TET2-nonmutant background were not al-
tered when JAK2 V617F was acquired on a TET2-
mutant background (Fig. 3E). The most up-reg-
ulated gene cluster across all comparisons was 
translational machinery when JAK2 V617F was 
acquired on a TET2-nonmutant background, and 
the most down-regulated gene cluster was cell-
cycle progression when JAK2 V617F was acquired 
on a TET2-mutant background.
To investigate further whether prior mutation 
of TET2 influences the transcriptional response 
to JAK2 V617F, we compared genes that were 
up-regulated when JAK2 V617F was acquired by 
TET2-nonmutant cells with those that were 
down-regulated when JAK2 V617F was acquired 
by TET2-mutant cells. This approach identified 
10 genes that were discordantly regulated by 
JAK2 V617F, depending on the TET2 genotype 
(Fig. 3F). These results were validated for all six 
genes tested (Fig. S5B in Supplementary Appen-
dix 1). Six of the genes have been implicated in 
DNA replication17 (MCM2, MCM4, and MCM5) or 
regulation of mitosis (AURKB,18 FHOD1,19 and 
TK120). These results are consistent with those in 
our functional studies of single hematopoietic 
stem cells and progenitor cells, which revealed 
increased proliferation when JAK2 V617F was ac-
quired by TET2-nonmutated but not TET2-mutated 
cells (Fig. 3A).
Together these data show that acquisition of 
a prior TET2 mutation dramatically altered the 
transcriptional consequences of JAK2 V617F in a 
cell-intrinsic manner. In particular, it prevented 
JAK2 V617F from up-regulating genes associated 
with proliferation.
Influence of Mutation Order on Clinical 
Presentation, Risk of Thrombosis, and 
Sensitivity to JAK Inhibition
In our initial patient cohort, the ratio of patients 
with polycythemia vera to those with essential 
thrombocythemia appeared to be greater among 
JAK2-first patients than among TET2-first patients 
(Fig. 2A). To explore this further, a follow-up co-
hort involving 918 patients was screened to iden-
tify 90 patients who harbored both JAK2 and TET2 
mutations. Copy-number–corrected variant allele 
fractions for both mutations were used to identify 
24 patients (18 JAK2-first patients and 6 TET2-first 
patients) in whom mutation order could be un-
ambiguously determined (see the Supplementary 
Methods section in Supplementary Appendix 1). To 
investigate the clinical relevance of mutational or-
der, we combined both cohorts (a total of 48 pa-
tients) for further analyses. As compared with 
TET2-first patients, JAK2-first patients presented at 
a younger age (mean, 60.71 years vs. 71.17 years; 
P = 0.002) (Fig. 4A), were more likely to present 
with polycythemia vera (P = 0.05) (Fig. 4B), and, 
despite presenting at a younger age, were more 
likely to have a thrombotic event (P = 0.002 by mul-
tivariate analysis) (Fig. 4C). In the JAK2-first group, 
4 patients had cardiac events (3 had myocardial 
infarction, and 1 had unstable angina), 2 had a 
transient ischemic attack, 2 had portal-vein throm-
boses, 2 had splanchnic-vein thrombosis, 1 had 
deep-vein thromboses, and 1 had calf-vein throm-
boses (1 patient had a transient ischemic attack, 
myocardial infarction, and splanchnic-vein throm-
bosis). In the TET2-first group, 1 patient had deep-
vein thromboses and 1 had a cardiac event (un-
stable angina). Patients in whom mutation order 
could not be unambiguously determined had an 
intermediate rate of thrombosis-free survival. Al-
though this small retrospective cohort study re-
quires confirmation in a prospective study, these 
data suggest that mutation order influences clini-
cal presentation and outcome.
To explore the implications of mutation order 
for therapy, we studied the effect of ruxolitinib (an 
inhibitor of JAK1 and JAK2) on colony formation. 
Although ruxolitinib is not specific for mutant 
JAK2,21 it has been shown to inhibit increased pro-
liferation of splenocytes and erythroblasts in a 
mouse model.22 The proportions of single-mutant 
colonies from all four JAK2-first patients were re-
duced after the administration of ruxolitinib, as 
were the proportions of double-mutant colonies in 
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three of four patients (Fig. 4D). By contrast, in all 
four TET2-first patients, the proportions of single-
mutant and double-mutant colonies were essen-
tially unchanged after the administration of ruxoli-
tinib. These results indicate that mutant progenitors 
from JAK2-first patients are more sensitive to JAK2
inhibition.
These data suggest that mutation order affects 
the proliferation of progenitors and terminal cell 
expansion, thereby influencing clinical presentation, 
the risk of thrombosis, and the response in vitro to 
targeted therapy (Fig. 4E).
 Discussion
We found that the order in which somatic muta-
tions were acquired influenced the behavior of 
stem and progenitor cells and clonal evolution, as 
well as the clinical presentation and risk of throm-
bosis among patients with myeloproliferative neo-
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plasms. Prior mutation of TET2 dramatically influ-
enced the transcriptional program activated by 
JAK2 V617F; this provides a molecular basis for the 
effect of mutation order. These results have clinical 
implications for patients, including the prediction 
that mutation order may influence response to 
therapy.
Mutation in either TET2 or JAK2 may occur first 
in all three subtypes of myeloproliferative neo-
plasms, but JAK2-first patients are significantly 
more likely to have polycythemia vera. These data 
confirm and extend the results of previous studies 
involving small numbers of TET2-first patients,23 
JAK2-first patients,24 or both.25 The fitness of clones 
in vivo may not always relate directly to their in 
vitro capacity, and cell-surface markers may be al-
tered by individual JAK2 or TET2 mutations. How-
ever, the consequences of mutation order that we 
describe in primary cells from patients are consis-
tent with several lines of in vivo evidence. TET2 
mutations have been shown to give rise to clonal 
expansions in elderly persons with normal blood 
counts,26 and in xenograft studies involving two 
patients, a double-mutant TET2–JAK2 clone was 
outcompeted by its TET2 single-mutant ancestor.23 
Moreover, in genetically modified mice, expression 
of JAK2 V617F resulted in increased erythropoiesis, 
whereas inactivation of TET2 had no effect on 
erythropoiesis.27,28 In experiments of serial repopu-
lation, inactivation of TET2 was shown to cause 
hematopoietic stem-cell expansion, whereas ex-
pression of JAK2 V617F was associated with either 
no hematopoietic stem-cell advantage29,30 or a dis-
advantage.31,32
Our data suggest a model for the effects of 
mutation order on the biology of myeloproliferative 
neoplasms (Fig. 4E). In TET2-first patients, TET2 
single-mutant hematopoietic stem and progenitor 
cells expand but do not give rise to excess differen-
tiated megakaryocytic and erythroid cells until 
subsequent acquisition of a JAK2 mutation. By 
contrast, in JAK2-first patients, JAK2 single-mutant 
hematopoietic stem and progenitor cells do not 
expand until acquisition of a TET2 mutation, but 
they are able to generate increased numbers of 
megakaryocytic and erythroid cells. This model is 
consistent with the early clinical presentation of 
JAK2-first patients, since they have a more rapid 
generation of excess megakaryocytic and erythroid 
cells and abnormal blood counts. It is also consis-
tent with the altered behavior of hematopoietic 
stem and progenitor cells that we observed.
At least three mechanisms that are not mutu-
ally exclusive may contribute to the influence of 
mutation order. First, the initial mutation may alter 
the cellular composition of the neoplastic clone, 
including early stem cells and progenitors and 
their differentiated progeny. As a consequence, 
after acquisition of the second mutation, the dou-
ble-mutant subclone will find itself in a cellular 
Figure 3 (facing page). Influence of Mutation Order on 
Proliferation of Stem and Progenitor Cells and Expres-
sion of Progenitor Genes.
In Panel A, the bar graph shows the average number  
of cells (clone size) that were present at 10 days in cul-
tures of hematopoietic stem and progenitor cells 
(HSPCs) of different genotypes. Bars represent non-
mutant, single-mutant, and double-mutant (both TET2 
and JAK2) clones. In the three TET2-first patients, the 
size of TET2 single-mutant clones did not differ signifi-
cantly from that of nonmutant clones (P = 0.24 by the  
t-test) or double-mutant clones (P = 0.07 by the t-test). 
By contrast, in the four JAK2-first patients, JAK2 single-
mutant clones were significantly larger than nonmu-
tant clones (P = 0.05 by the t-test) and double-mutant 
clones (P = 0.04 by the t-test). T bars indicate standard 
errors, single asterisks P<0.05, and double asterisks 
P<0.01. In Panel B, the number of secondary colony-
forming cells created per HSPC is shown for two pa-
tients who had a TET2 mutation followed by a JAK2 
V617F mutation and four patients who had a JAK2  
mutation followed by a TET2 mutation. HSPCs that  
acquire JAK2 V617F on a TET2-mutant background,  
as compared with TET2 single-mutant HSPCs, produce 
fewer colony-forming cells (mean, 3 colony-forming 
cells vs. 12 colony-forming cells; P = 0.002 by the  
t-test), whereas those that acquire TET2 mutations on 
a JAK2 single-mutant background, as compared with 
JAK2 single-mutant HSPCs, produce more colony-
forming cells (mean, 27 colony-forming cells vs. 16 col-
ony-forming cells; P = 0.01 by the t-test). In Panel C, 
each bar graph shows the percentage of total HSPCs of 
each genotype measured in five TET2-first patients 
and six JAK2-first patients. The percentage of HSPCs 
that retained the first mutation alone was higher in 
TET2-first patients than in JAK2-first patients. In Panel 
D, each bar graph shows the percentage of BFU-E col-
onies of each genotype in five TET2-first patients and 
six JAK2-first patients. In contrast to the proportion of 
mutant HSPCs (Panel C), the TET2-first BFU-E com-
partment is skewed toward the double-mutant clone. 
The JAK2-first BFU-E compartment is similar to the 
HSPC compartment. In Panel E, each Venn diagram 
shows the overlap in genes that are commonly up-reg-
ulated (left diagram, 54 common genes) or down-regu-
lated (right diagram, 61 common genes) when JAK2 
V617F is acquired on different backgrounds. In Panel F, 
the Venn diagram shows the numbers of genes that 
are up-regulated when JAK2 V617F is acquired on a 
nonmutant background overlapped with those that are 
down-regulated when JAK2 V617F is acquired on a 
TET2-mutant background. The 10 genes that followed 
this pattern are listed in the box.
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environment that is determined by the identity of 
the first mutation. Cellular interactions between 
genetically distinct subclones may conceivably take 
several forms, including direct competition for 
available niches and feedback effects of differenti-
ated cells on stem-cell and progenitor compart-
ments.33
Second, the initial mutation may mandate dis-
tinct cellular pathways as targets for subsequent 
mutations that are able to provide a growth ad-
vantage. The order in which TET2 and JAK2 are 
acquired may therefore dictate which additional 
mutations are acquired and thus influence the 
pathogenesis of disease.
Third, the initial mutation may modify the epi-
genetic program of hematopoietic stem cells and 
progenitor cells and thus alter the consequences 
of the second mutation. TET2 alters the epigen-
etic landscape by converting 5-methylcytosine to 
5-hydroxymethylcytosine,34,35 and it also promotes 
the addition of N-acetylglucosamine to histones.36 
Our results indicate that prior mutation of TET2 
alters the transcriptional consequences of JAK2 
V617F in a cell-intrinsic manner and prevents 
JAK2 V617F from up-regulating a proliferative pro-
gram. The frequency with which epigenetic reg-
ulators are mutated in hematologic37 and nonhe-
matologic38 cancers raises the possibility that 
mutation order influences the biology of many 
different cancers.
Supported by Leukemia and Lymphoma Research, Cancer 
Research UK, the Kay Kendall Leukaemia Fund, the National 
Institute for Health Research Cambridge Biomedical Research 
Centre, the Cambridge Experimental Cancer Medicine Centre, 
and the Leukemia and Lymphoma Society of America (all to Dr. 
Figure 4 (facing page). Clinical Significance of Mutation Order in Myeloproliferative Neoplasms.
In Panel A, the mean age at presentation of 48 patients with myeloproliferative neoplasms in whom mutation order 
was determined is shown. On average, TET2-first patients presented 10.46 years later than JAK2-first patients 
(P = 0.002 by the t-test; P = 0.02 by two-way analysis of variance accounting for order of acquisition of mutation, sex, 
white-cell count, and phenotype of the myeloproliferative neoplasm). I bars indicate standard errors, and double as-
terisks P<0.01. In Panel B, histograms represent the number of patients who received a diagnosis of essential 
thrombocythemia (ET) or polycythemia vera (PV). JAK2-first patients were more likely to receive a diagnosis of PV 
(P = 0.05 by the chi-square test). The single asterisk indicates P<0.05. In Panel C, a Kaplan–Meier curve shows 
thrombosis-free survival among all 48 patients in whom mutation order was determined. JAK2-first status was iden-
tified as an independent risk factor for thrombotic events in addition to the known risk factor of age (P = 0.002 by 
multivariate analysis for mutational order and P = 0.01 by Cox proportional-hazards model for age taking into ac-
count age, prior thrombosis, sex, subtype of myeloproliferative neoplasm, white-cell count, receipt of cytoreductive 
therapy, and order of mutations). In Panel D, the graph shows the relative sensitivity of colonies with distinct geno-
types to ruxolitinib in a colony-forming cell assay (4 TET2-first patients and 4 JAK2-first patients, 35 to 66 colonies 
picked per patient). In TET2-first patients, single-mutant colonies had a TET2 mutation alone, and in JAK2-first pa-
tients, single-mutant colonies had a JAK2-heterozygous or JAK2-homozygous mutation. Single-mutant clones in 
JAK2-first patients were more sensitive to ruxolitinib (left side, P<0.01 by the one-tailed t-test). Double-mutant 
clones (those bearing both JAK2 and TET2 mutations) in JAK2-first patients were also more sensitive to ruxolitinib 
as compared with clones from TET2-first patients (right side, P = 0.03 by the one-tailed t-test). In Panel E, the way in 
which the order of mutation acquisition influences the evolution of disease is shown. This model depicts the man-
ner in which single hematopoietic units (left), consisting of stem cells, progenitors, and differentiated cells, acquire 
mutations over time. Some units are hyperproliferative and produce excess differentiated cells that contribute to the 
disease phenotype. The numbers represent the acquisition of the first mutation (1), second mutation (2), and JAK2 
V617F homozygosity (3). Patients who acquire a TET2 mutation first gain a self-renewal advantage but do not over-
produce downstream progeny. The expansion of the TET2-alone clone (bold borders) without excess differentiated 
cells leads to clonal expansion without immediate clinical presentation. Hematopoietic stem cells that acquire a sec-
ondary JAK2 mutation (pink fill) compete with the TET2-alone clone, and their increased proliferation at the progen-
itor level drives an overproduction of terminal cells. When homozygosity is acquired as a third event (red fill), this 
clone has limited space to expand because of the high self-renewal activity of TET2-alone and TET2–JAK2–heterozy-
gous clones. Patients who acquire a JAK2 mutation first (pink fill, lower panel) produce excess differentiated cells in 
the absence of a distinct self-renewal advantage in the hematopoietic stem cells. When a secondary TET2 mutation 
is acquired, hematopoietic stem cells obtain a self-renewal advantage and JAK2–TET2–mutant cells expand at the 
stem-cell level. Hematopoietic stem cells with loss of heterozygosity of JAK2 V617F (acquired before or after the 
TET2 mutation) (red fill) also have space to expand and result in a more pronounced excess of differentiated cells. 
This excess production would explain both the presentation as a polycythemia vera and the elevated risk of throm-
botic events in JAK2-first patients.
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